Atlas Trials

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Clinical trial NCT03914612 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03914612
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Endometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaRecurrent Endometrial AdenocarcinomaRecurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Dedifferentiated CarcinomaRecurrent Endometrial Endometrioid AdenocarcinomaRecurrent Endometrial Mixed Cell Adenocarcinoma
Start date
2019-08-22
Primary completion
2022-12-16
Enrollment
813

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.